Uncategorized

Agios scraps sickle cell drug

Published

on

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version